Undisclosed highly tumour selective bispecific T-cell engager / LabGenius Therapeutics - LARVOL DELTA

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025 (Businesswire) - "LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE)....For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company’s lead optimisation platform, EVA, was used to discover and concomitantly optimise a TCE with improved killing selectivity, potency, efficacy, and manufacturability."

Preclinical • Oncology